Diagnostic accuracy of magnetic resonance, computed tomography and contrast enhanced ultrasound in radiological multimodality assessment of peribiliary liver metastases

Purpose We compared diagnostic performance of Magnetic Resonance (MR), Computed Tomography (CT) and Ultrasound (US) with (CEUS) and without contrast medium to identify peribiliary metastasis. Methods We identified 35 subjects with histological proven peribiliary metastases who underwent CEUS, CT and MR study. Four radiologists evaluated the presence of peribiliary lesions, using a 4-point confidence scale. Echogenicity, density and T1-Weigthed (T1-W), T2-W and Diffusion Weighted Imaging (DWI) signal intensity as well as the enhancement pattern during contrast studies on CEUS, CT and MR so as hepatobiliary-phase on MRI was assessed. Results All lesions were detected by MR. CT detected 8 lesions, while US/CEUS detected one lesion. According to the site of the lesion, respect to the bile duct and hepatic parenchyma: 19 (54.3%) were periductal, 15 (42.8%) were intra-periductal and 1 (2.8%) was periductal-intrahepatic. According to the confidence scale MRI had the best diagnostic performance to assess the lesion. CT obtained lower diagnostic performance. There was no significant difference in MR signal intensity and contrast enhancement among all metastases (p>0.05). There was no significant difference in CT density and contrast enhancement among all metastases (p>0.05). Conclusions MRI is the method of choice for biliary tract tumors but it does not allow a correct differential diagnosis among different histological types of metastasis. The presence of biliary tree dilatation without hepatic lesions on CT and US/CEUS study may be an indirect sign of peribiliary metastases and for this reason the patient should be evaluated by MRI.

[1]  A. Warshaw,et al.  Extrahepatic biliary obstruction caused by metastatic breast carcinoma. , 1979, Annals of internal medicine.

[2]  B. Choi,et al.  Gadoxetic acid‐enhanced MRI with MR cholangiography for the preoperative evaluation of bile duct cancer , 2013, Journal of magnetic resonance imaging : JMRI.

[3]  Myeong-Jin Kim,et al.  Staging of extrahepatic cholangiocarcinoma , 2008, European Radiology.

[4]  Massimo Midiri,et al.  Characterisation of focal liver lesions undetermined at grey-scale US: contrast-enhanced US versus 64-row MDCT and MRI with liver-specific contrast agent , 2010, La radiologia medica.

[5]  S. Schoenberg,et al.  Cross-sectional imaging of biliary tumors: current clinical status and future developments , 2004, European Radiology.

[6]  Evaluation of Perihilar Biliary Strictures: Does DWI Provide Additional Value to Conventional MRI? , 2015, AJR. American journal of roentgenology.

[7]  F. Izzo,et al.  Hepatocellular carcinoma and liver metastases: clinical data on a new dual-lumen catheter kit for surgical sealant infusion to prevent perihepatic bleeding and dissemination of cancer cells following biopsy and loco-regional treatments , 2015, Infectious Agents and Cancer.

[8]  F. Izzo,et al.  Early Assessment of Colorectal Cancer Patients with Liver Metastases Treated with Antiangiogenic Drugs: The Role of Intravoxel Incoherent Motion in Diffusion-Weighted Imaging , 2015, PloS one.

[9]  B. Choi,et al.  Gadobutrol-enhanced, Three-Dimensional, Dynamic MR Imaging With MR Cholangiography for the Preoperative Evaluation of Bile Duct Cancer , 2010, Investigative radiology.

[10]  F. Izzo,et al.  The target sign in colorectal liver metastases: an atypical Gd-EOB-DTPA “uptake” on the hepatobiliary phase of MR imaging , 2015, Abdominal Imaging.

[11]  M. Tillich,et al.  Multiphasic helical CT in diagnosis and staging of hilar cholangiocarcinoma. , 1998, AJR. American journal of roentgenology.

[12]  Roberta Fusco,et al.  Immediate Adverse Reactions to Gadolinium-Based MR Contrast Media: A Retrospective Analysis on 10,608 Examinations , 2016, BioMed research international.

[13]  Celia P. Corona-Villalobos,et al.  Imaging of the patient with a biliary tract or primary liver tumor. , 2014, Surgical oncology clinics of North America.

[14]  F. Wacker,et al.  Radiological diagnosis in cholangiocarcinoma: Application of computed tomography, magnetic resonance imaging, and positron emission tomography. , 2015, Best practice & research. Clinical gastroenterology.

[15]  H. Bismuth,et al.  Intrahepatic cholangioenteric anastomosis in carcinoma of the hilus of the liver. , 1975, Surgery, gynecology & obstetrics.

[16]  Young Kon Kim,et al.  Hilar cholangiocarcinoma: value of adding DW imaging to gadoxetic acid-enhanced MR imaging with MR cholangiopancreatography for preoperative evaluation. , 2014, Radiology.

[17]  J. Kleijnen,et al.  Rapid fetal fibronectin testing to predict preterm birth in women with symptoms of premature labour: a systematic review and cost analysis. , 2013, Health technology assessment.

[18]  A. Kim,et al.  Biliary obstruction in metastatic disease: thin-section helical CT findings , 2003, Abdominal Imaging.

[19]  K. Sung,et al.  Clinical outcomes after percutaneous biliary interventions in patients with malignant biliary obstruction caused by metastatic gastric cancer , 2012, Acta radiologica.

[20]  F. Izzo,et al.  Irreversible electroporation of hepatocellular carcinoma: preliminary report on the diagnostic accuracy of magnetic resonance, computer tomography, and contrast-enhanced ultrasound in evaluation of the ablated area , 2016, La radiologia medica.

[21]  M Westwood,et al.  Contrast-enhanced ultrasound using SonoVue® (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effecti , 2013, Health technology assessment.

[22]  O. Catalano,et al.  Contrast-enhanced ultrasound in the characterization of complex cystic focal liver lesions. , 2015, Ultrasound in medicine & biology.

[23]  Myeong-Jin Kim,et al.  Comparison of gadoxetic acid‐enhanced dynamic imaging and diffusion‐weighted imaging for the preoperative evaluation of colorectal liver metastases , 2011, Journal of magnetic resonance imaging : JMRI.

[24]  A. Dohan,et al.  Intrahepatic and hilar mass-forming cholangiocarcinoma: Qualitative and quantitative evaluation with diffusion-weighted MR imaging. , 2015, European journal of radiology.

[25]  Jeong Min Lee,et al.  ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents , 2015, European Radiology.

[26]  J Ricke,et al.  ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[27]  Antonella Petrillo,et al.  A randomized phase 3 study on the optimization of the combination of bevacizumab with FOLFOX/OXXEL in the treatment of patients with metastatic colorectal cancer-OBELICS (Optimization of BEvacizumab scheduLIng within Chemotherapy Scheme) , 2016, BMC Cancer.

[28]  E. Hahn,et al.  Detection of liver metastases: comparison of contrast‐enhanced wide‐band harmonic imaging with conventional ultrasonography. , 2001, Journal of ultrasound in medicine : official journal of the American Institute of Ultrasound in Medicine.

[29]  C. Johnson,et al.  Cholangiocarcinoma: diagnosis and evaluation of resectability by CT and sonography as procedures complementary to cholangiography. , 1988, AJR. American journal of roentgenology.

[30]  F. Izzo,et al.  Surveillance of HCC Patients after Liver RFA: Role of MRI with Hepatospecific Contrast versus Three-Phase CT Scan—Experience of High Volume Oncologic Institute , 2013, Gastroenterology research and practice.

[31]  H. Kitajima,et al.  Primary biliary tract malignancies: MRI spectrum and mimics with histopathological correlation , 2015, Abdominal Imaging.